DrLarryPTilley-050320
MMR Vaccine Likely Why COVID-19 Rarely Hitting Young According to World Organization
03 mai 2020 07h02 HE | World Organization
ATLANTA, May 03, 2020 (GLOBE NEWSWIRE) -- The report MMR Vaccine Link to COVID-19: Fewer Deaths and Milder Cases from SARS-CoV-2 in Measles-Rubella Vaccinated Populations reveals that the MMR...
COVID-19 Death Rate by Age
MMR Vaccine May Protect People Over 50 from COVID-19 According to World Organization
29 avr. 2020 09h01 HE | World Organization
ATLANTA, April 29, 2020 (GLOBE NEWSWIRE) -- Epidemiological data revealed in an MMR vaccines and COVID-19 investigation by World Organization suggests it is possible that widely deployed MMR and...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech und Pfizer schließen erste Dosierungs-Kohorte der Phase-1/2-Studie mit COVID-19-Impfstoffkandidaten in Deutschland ab
29 avr. 2020 03h42 HE | BioNTech SE
MAINZ, Deutschland und NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen“), und Pfizer Inc. (NYSE: PFE) haben bekannt gegeben, dass die erste...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
29 avr. 2020 03h42 HE | BioNTech SE
MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTech’s...
drlarrytilley
Possible Connection of MMR Vaccine to Mild COVID-19 Cases Studied by Dr. Larry P. Tilley, World Organization Advisory Board Member
28 avr. 2020 07h51 HE | World Organization
ATLANTA, April 28, 2020 (GLOBE NEWSWIRE) -- World Organization Advisory Board Member Dr. Larry Tilley is investigating a possible link between MMR vaccines and COVID-19. Tilley’s investigation began...
Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
27 avr. 2020 09h30 HE | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been...
emergent logo.jpg
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
23 avr. 2020 18h51 HE | Emergent BioSolutions
Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic useAgreement valued...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech und Pfizer geben Genehmigung des Paul-Ehrlich-Instituts für erste klinische Studie von COVID-19-Impfstoffkandidaten bekannt
22 avr. 2020 05h00 HE | BioNTech SE
Beginn der ersten klinischen Studie für einen COVID-19-Impfstoff in DeutschlandDosisfindung in der Eskalationsphase im Bereich von 1µg bis 100µg Impfstoffherstellung für klinische Studien in BioNTechs...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
22 avr. 2020 05h00 HE | BioNTech SE
First COVID-19-related clinical trial to start in GermanyInitial dose escalation phase to target dose range of 1µg to 100µg Clinical supply from BioNTech’s GMP-certified mRNA production facilities in...
Picture 1
Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19
20 avr. 2020 09h00 HE | Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that based on molecular...